Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.26
-0.0100-0.79%
Post-market: 1.280.0200+1.59%19:51 EDT
Volume:436.94K
Turnover:555.43K
Market Cap:71.28M
PE:-4.18
High:1.34
Open:1.28
Low:1.21
Close:1.27
Loading ...

IceCure Medical price target raised to $4.60 from $4.16 at Brookline

TIPRANKS
·
27 Nov 2024

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
26 Nov 2024

IceCure Medical GAAP EPS of $0.22 , revenue of $2.41M

seekingalpha
·
26 Nov 2024

IceCure Medical’s Promising Growth and FDA Anticipation

TIPRANKS
·
26 Nov 2024

IceCure Medical reports 36% sales growth in first nine months of 2024

TIPRANKS
·
26 Nov 2024

Press Release: IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense(R) Cryoablation

Dow Jones
·
26 Nov 2024

IceCure Medical’s Cryoablation Innovation Gains Momentum

TIPRANKS
·
25 Nov 2024

BRIEF-Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice Of Allowance From Japan's Patent Office

Reuters
·
25 Nov 2024

IceCure Medical receives Notice of Allowance from Japan’s Patent Office

TIPRANKS
·
25 Nov 2024

Icecure Medical Ltd: Terumo Corporation Plans to File for Regulatory Approval of Prosense for Breast Cancer in 2025

THOMSON REUTERS
·
25 Nov 2024

Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance From Japan's Patent Office

THOMSON REUTERS
·
25 Nov 2024

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

PR Newswire
·
25 Nov 2024

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

PR Newswire
·
20 Nov 2024

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

PR Newswire
·
19 Nov 2024

Market Sentiment Around Loss-Making IceCure Medical Ltd (NASDAQ:ICCM)

Simply Wall St.
·
13 Nov 2024

Icecure Medical’s ProSense System Gains Favorable FDA Panel Recommendation and Strong Financial Position Supports Buy Rating

TIPRANKS
·
10 Nov 2024

BUZZ-IceCure up after FDA panel backs use of its breast cancer treatment system

Reuters
·
08 Nov 2024

Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.

Dow Jones
·
08 Nov 2024

IceCure Medical’s ProSense® Gains FDA Panel Support

TIPRANKS
·
08 Nov 2024

BRIEF-FDA Advisory Panel Backs Icecure's Prosense Cryoablation For Early-Stage Low Risk Breast Cancer

Reuters
·
08 Nov 2024